Carregant...
DR-05 TREATMENT AND PROGNOSIS AFTER BEVACIZUMAB FAILURE IN RECURRENT GLIOBLASTOMA: THE CLEVELAND CLINIC EXPERIENCE
BACKGROUND: Bevacizumab (BEV) is FDA approved for treatment of recurrent glioblastoma (rGBM). There are no good treatment options for rGBM after progression on BEV. Our aim is to identify the patterns of treatment after initial progression on BEV and to estimate the median progression free survival...
Guardat en:
| Autors principals: | , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Oxford University Press
2014
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4218044/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou252.5 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|